It has been suggested recently that, in some quarters, IVF be offered as ®rst-line therapy to all infertile couples, regardless of the type of infertility. Hence, the time was thought right to scrutinise the results and complications of ovulation induction for anovulatory infertile couples. In addition to examining the outcome of conventional treatment with gonadotrophins and clomiphene citrate, special attention has been paid to the suggested improvement of results by taking into account the in¯uence of obesity and the use of a low-dose gonadotrophin protocol. The possible contribution of more recent additions to the armamentarium such as insulin sensitizers and aromatase inhibitors, although still at an infant stage, are promising. Attention has been given to the prevention and treatment of ovarian hyperstimulation syndrome. The use of intra-uterine insemination (IUI) as an adjuvant to induction of ovulation and controlled ovarian hyperstimulation (COH) is examined. The very ®rm conclusion has been reached that, taking into account ef®ciency, complication rate and cost of treatment, at this stage, women with hypogonadotrophic hypogonadism or polycystic ovary syndrome should be offered accepted methods of ovulation induction and that couples with`unexplained' or`multifactorial subfertility' should still be exposed to COH with IUI and only after the failure of these therapies, be offered IVF.
Introduction
Until the early 1960s, ef®cient treatment of anovulationÐand for that matter also of all other types of infertilityÐwas virtually nonexistent. To couples who consulted us because they did not succeed in achieving a pregnancy we could offer only psychological support, explanation of proper technique and frequency and timing of intercourse and, in some countries, arti®cial donor insemination for cases of severe male infertility.
During the 1960s and 1970s a veritable avalanche of drugs, methods and modalities for effective treatment of infertility, particularly of anovulation, cameÐalmost simultaneouslyÐfrom several directions.
In 1961, Greenblatt and his co-workers published in the Journal of the American Medical Association the ®rst results achieved by application of clomiphene (then known as MRL-41) (Greenblatt et al., 1961) . Since then, thousands of anovulatory women have been able to enjoy maternity thanks to this simple, cheap and relatively safe treatment.
Gemzell and his co-workers announced the ®rst successful induction of ovulation using human pituitary gonadotrophins in 1958, and the ®rst pregnancy in 1960 (Gemzell et al., 1958 (Gemzell et al., , 1960 . One year later, Bettendorf and his group reported on similar experience (Bettendorf et al., 1961) . Both Gemzell and Bettendorf were also able to achieve pregnancies in hypophysectomized patients by application of human pituitary gonadotrophins (Bettendorf, 1963; Gemzell, 1964) , a feat which was certainly a major breakthrough. Concomitant with these efforts, Lunenfeld and his group succeeded in extracting a potent gonadotrophin material from the urine of menopausal women (Lunenfeld, 1963) and showed that this preparation enabled the induction of ovulation and pregnancy in a large series of amenorrhoeic women Lunenfeld et al., 1970) .
During the 1970s, two additional modalities for treatment of anovulation were introducedÐgonadotrophin-releasing hormone and prolactin-inhibiting agents.
The gonadotrophin-releasing hormone (GnRH) was isolated, its structure established (Matsuo et al., 1971a,b; Gullemin, 1978; Schally et al., 1978) , and shortly afterwards a preparation of native GnRH, synthesized in the laboratory, was made available for clinical use. It took several years until Knobil (1980) showed that in order to be effective, GnRH must be applied not continuously but in pulses precisely spaced in time (Knobil, 1980) . Indeed, the pulsatile GnRH therapy proved to be very effective in inducing ovulation and pregnancy in women who suffered from hypogonadotrophic amenorrhoea of hypothalamic origin (Crowley and MacArthur, 1980; Leyendecker et al., 1980) . Prolactin, a peptide secreted by the pituitary gland was puri®ed a year later . In the same year, a speci®c assay for human prolactin was made available , and this made it possible to show that excessive secretion of prolactin might result in impaired pulsatility of LH discharge and cause amenorrhoea or anovulation with or without galactorrhoea (Bohnet et al., 1975 (Bohnet et al., , 1976 . During a 3-year period, between 1974 and 1977, a number of publications appeared which showed unequivocally that bromocryptine (a lysergic acid derivative) is ef®cient in reducing the circulating levels of prolactin and also in restoring a balanced LH pulsatility and, consequently, re-establishing normal menstruation and ovulation (del Pozo et al., 1974; Thorner et al., 1974; Jacobs et al., 1976; Kleinberg et al., 1977) . Later on, many other prolactin-inhibiting agents were introduced, and it has been shown that these drugs not only regulated ovulatory and menstrual function but were also able to inhibit the growth of pituitary adenomas.
Ovulation induction agents

Weight loss
While female age is probably the most important single factor affecting fertility, maternal weight also seems to have a substantial effect. Obese women are less fertile in both natural and ovulation induction cycles and have higher rates of miscarriage than their counterparts of normal weight; they also require higher doses of ovulation-inducing agents (HamiltonFairley et al., 1992; Zaadstra et al., 1993; Crosignani et al., 1994) . In a study examining the effect of a weight loss programme on 67 anovulatory, obese women who had failed to conceive with conventional treatment, the mean weight loss was 10.2 kg (Clark et al., 1998) . Following the loss of weight, 60 of the 67 women resumed ovulation and 52 achieved a pregnancy, 18 of them spontaneously. In addition to these impressive results, only 18% of these pregnancies miscarried compared with 75% of pregnancies achieved before the weight loss (Clark et al., 1998) .
Some 80% of obese women with polycystic ovary syndrome (PCOS) have insulin resistance and a consequent hyperinsulinaemia. They almost inevitably have the stigmata of hyperandrogenism and irregular or absent ovulation. Insulin stimulates LH and ovarian androgen secretion and decreases sex hormone-binding globulin (SHBG) concentrations (Poretsky et al., 1999) . Central obesity and body mass index (BMI) are major determinants of insulin resistance, hyperinsulinaemia and hyperandrogenaemia.
The most signi®cant factors that adversely in¯uence pregnancy rate using gonadotrophins are age, excess body weight (HamiltonFairley et al., 1992) and insulin resistance (Dale et al., 1998) . Whereas advancing age has an adverse effect on all treatment for infertility but obviously cannot be overcome, the successful treatment of obesity and insulin resistance is capable of reversing their deleterious effects (of which there are several) on the outcome of treatment. More gonadotrophins are required to achieve ovulation in insulin-resistant women (Homburg, 1996; Dale et al., 1998) . Obese women being treated with low-dose therapy have inferior pregnancy and miscarriage rates (HamiltonFairley et al., 1992) , while both obese (White et al., 1996) and insulin-resistant (Dale et al., 1998) women with PCOS, even on low-dose FSH stimulation, have a much greater tendency to a multifollicular response and thus a relatively high cycle cancellation rate in order to avoid hyperstimulation.
As obesity therefore expresses and exaggerates the signs and symptoms of insulin resistance, then loss of weight can reverse this process by improving ovarian function and the associated hormonal abnormalities. Curiously, in obese women with PCOS, a loss of just 5±10% of body weight is enough to restore reproductive function in 55±100% within 6 months of weight reduction (Pasquali et al., 1989; Kiddy et al., 1992) . Weight loss has the undoubted advantages of being effective and cheap with no side effects, and should be the ®rst line of treatment in obese women with anovulatory infertility.
Clomiphene citrate
It is now clear that the administration of even small amounts of FSH into the system will induce ovulation and pregnancy in a large proportion of anovulatory women who have hypothalamicpituitary dysfunction (Group II). This may be achieved indirectly, with clomiphene citrate or pulsatile GnRH (pGnRH) or directly by administration of a preparation containing FSH. Clomiphene citrate should be the ®rst line of treatment for those with absent or irregular ovulation but who have normal basal levels of endogenous estradiol. It is given in a dose of 50±250 mg per day for 5 days from day 2, 3, 4 or 5 of spontaneous or induced bleeding, starting with the lowest dose and raising the dose in increments of 50 mg per day per cycle until an ovulatory cycle is achieved. In practice, we almost inevitably use a starting dose of 100 mg per day from day 4 or 5 and have found no advantages of using a daily dose of more than 150 mg which seems to increase neither the ovulation rate nor follicular recruitment to any signi®cant degree (Dickey et al., 1997) . This type of regimen will cut down the number of`super¯uous' cycles of treatment until ovulation is achieved and until those resistant to clomiphene are identi®ed. A course of three to six ovulatory cycles is usually suf®cient to know whether pregnancy will be achieved using clomiphene citrate before moving on to more complex treatment, as~75% of the pregnancies achieved with clomiphene occur within the ®rst three cycles of treatment (Gysler et al., 1982) .
Clomiphene citrate will restore ovulation in approximately 80% of patients, but will result in pregnancy in only about 35± 40% (MacGregor et al., 1968; Gysler et al., 1982; Imani et al., 2002) . Additionally, around 20±25% of anovulatory women with normal FSH concentrations will not respond at all to clomiphene citrate and are considered to be`clomiphene-resistant' (Franks and Hamilton-Fairley, 1996; Imani et al., 1998) . Patients who do not respond to clomiphene are likely to be more obese, insulinresistant and hyperandrogenic than those who do respond (Imani et al., 1998) . As clomiphene citrate induces a discharge of LH as well as FSH, and elevated LH concentrations are believed to impede conception, those women with high basal LH levels are also less likely to respond to clomiphene treatment (Homburg et al., 1988) . The large discrepancy between ovulation and pregnancy rates in patients treated with clomiphene citrate may in part be explained by elevated LH levels, but the most probable factor involved is the anti-estrogenic effects of clomiphene at the level of the endometrium and cervical mucus. While the depression of the cervical mucus, which occurs in~15% of patients, may be overcome by performing intra-uterine insemination (IUI), suppression of endometrial proliferation, unrelated to dose or duration of treatment but apparently idiosyncratic, indicates a poor prognosis for conception in our experience when endometrial thickness never reaches 8 mm. Monitoring of the clomiphene-treated cycle by ultrasound evaluation of follicular growth, endometrial thickness and even estradiol and progesterone concentrations on day 12±14 of the cycle is justi®ed by the identi®cation of those who are not responding or have depressed endometrial thickness, and is also helpful in the timing of natural intercourse or IUI. Although such monitoring implies added expense, this is neutralized by the prevention of protracted periods of possibly ineffective therapy and delay in the inception of more ef®cient treatment.
Several adjuvants to clomiphene treatment have been suggested. The addition of an ovulatory dose of hCG (5000±10 000 IU) is only theoretically warranted when the reason for a nonovulatory response is that the LH surge is delayed or absent despite the presence of a well-developed follicle. Although the routine addition of hCG at mid-cycle seems to add little to the improvement of conception rates (Agrawal and Buyalos, 1995) we have found it very useful, if given when an ultrasonically demonstrated leading follicle attains a diameter of 18±24 mm, for the timing of intercourse or IUI.
The idea behind giving daily doses of dexamethasone, 0.5 mg at bedtime, as an adjunct to clomiphene therapy is that the suppression of adrenal androgen secretion may induce responsiveness to clomiphene in previous non-responders (mostly hyperandrogenic women with PCOS) with elevated concentrations of dehydroepiandrosterone sulphate (DHEAS) (Diamant and Evron, 1981; Daly et al., 1984) . Although this method meets with some success, medium-to long-term glucocorticoid steroid therapy often induces side effects including increased appetite and weight gainÐwhich is not an appealing proposition for women with PCOS. Recently, it has been claimed that similar doses of dexamethasone, taken only during the follicular phase of a clomiphene cycle, are bene®cial for clomiphene-resistant patients regardless of DHEAS levels (Trott et al., 1996) .
Aromatase inhibitors
As the discrepancy in ovulation and pregnancy rates with clomiphene citrate has been attributed to its anti-estrogenic action and oestrogen receptor depletion, aromatase inhibitors have been suggested as an alternative treatment. Letrozole, the best known aromatase inhibitor, does not have the adverse anti-estrogenic effects of clomiphene but, by suppressing oestrogen production, it mimics the central reduction of negative feedback through which clomiphene works. It has been shown to be effective, in early trials, in inducing ovulation and pregnancy in women with anovulatory PCOS and inadequate clomiphene response (Mitwally and Casper, 2001a) and improving ovarian response to FSH in poor responders (Mitwally and Casper, 2001b) . Although these are early days in terms of accumulation of evidence from larger trials, some encouragement may be taken from the solidity of the working hypothesis and the success of the initial experience.
Metformin
Many of the women requiring ovulation induction have PCOS associated with insulin resistance and hyperinsulinaemia. The strong association between hyperinsulinaemia and anovulation would suggest that a reduction of insulin concentrations could be of great importance. Weight loss for the obese can reverse this situation as mentioned above, but for those who fail to lose weight or who are of normal weight but hyperinsulinaemic, an insulinsensitizing agent such as metformin may well be indicated. Metformin is an oral biguanide that is well established for the treatment of hyperglycaemia but does not cause hypoglycaemia in normoglycaemic patients. The sum total of its actions is a decrease in insulin levels and, as a consequence, a lowering of circulating total and free androgen levels with a resulting improvement of the clinical sequelae of hyperandrogenism.
A large number of studies have been published on the effect of metformin in a dose of 1500±2000 mg per day in women with PCOS. The vast majority of these studies have demonstrated a signi®cant improvement in insulin concentrations, insulin sensitivity, and serum androgen concentrations accompanied by decreased LH and increased SHBG concentrations. The restoration of regular menstrual cycles by metformin has been reported in the large majority of published series and the reinstatement of ovulation occurred in 78±96% of patients (Velazquez et al., 1994; Nestler et al., 1998; Moghetti et al., 2000; Ibanez et al., 2001) .
In a randomized controlled trial (RCT) performed on clomiphene-resistant infertile patients with PCOS, compared with placebo, metformin markedly improved ovulation and pregnancy rates with clomiphene treatment . In a large study, 46 anovulatory obese women with PCOS who did not ovulate on metformin or placebo for 35 days were given 50 mg of clomiphene daily for 5 days while continuing metformin or placebo. Of those on metformin, 19 of 21 ovulated compared with 2 of 25 on placebo . In contrast, a similarly designed study did not demonstrate any superiority of metformin over placebo in the induction of ovulation in a group of women with clomiphene-resistant PCO (Ng et al., 2001) . The disparity of these results could be a matter of differences in patient selection, study design and dose of clomiphene used.
When women with clomiphene-resistant PCOS were administered FSH with or without pretreatment with metformin for 1 month in an RCT, those receiving metformin developed signi®cantly fewer large follicles, produced less estradiol and had fewer cycles cancelled due to excessive follicular development. The reduction of insulin concentrations induced by metformin seemed to favour a more orderly follicular growth in response to exogenous gonadotrophins for ovulation induction (De Leo et al., 1999) . In the one published study on the effects of metformin on clomiphene-resistant patients undergoing IVF/ICSI, the results of cycles preceded by treatment with metformin were compared retrospectively to those in which metformin was not given. Those receiving metformin had a decreased total number of follicles but no difference in the mean number of oocytes retrieved. There were more mature oocytes, embryos cleaved, increased fertilization and clinical pregnancy rates (70 versus 30%) in the metformin group (Stadtmauer et al., 2001) . These latter two studies would seem to con®rm that both obese (White et al., 1996) and insulin-resistant (Dale et al., 1998) women with PCOS have a much greater tendency to a multifollicular response and thus a relatively high cycle cancellation rate on low-dose FSH stimulation.
While the ef®ciency and safety of metformin as a single agent or in combination with clomiphene citrate or gonadotrophin for induction of ovulation in women with hyperinsulinaemic PCOS awaits further assurance, the evidence so far is encouraging (Homburg, 2002) .
Laparoscopic ovarian drilling
A further treatment option for women with anovulatory infertility associated with PCOS is laparoscopic ovarian drilling (LOD) by diathermy or laser. This`update' of ovarian wedge resection employs a unipolar coagulating current or puncture of the ovarian surface with a laser in four to ten places to a depth of 4±10 mm on each ovary. An analysis was conducted (Donesky and Adashi, 1996) of the ®rst 35 reports, mostly uncontrolled series, in which 82% of 947 patients ovulated following the operation and 63% conceived either spontaneously or after treatment with medications to which they had previously been resistant. A recent metaanalysis of six RCTs (Farquhar et al., 2001 ) mostly comparing LOD with gonadotrophin therapy, showed similar cumulative ongoing pregnancy rates after 6±12 months follow-up and three to six cycles of gonadotrophin therapy. This Cochrane analysis highlighted the main advantage of ovarian drillingÐa signi®cant reduction in multiple pregnancy rates compared with gonadotrophin therapy. Further possible advantages of LOD are a reported reduction in miscarriage rates (Abdel Gadir et al., 1990) , and the fact that it is an often successful`one-off' procedure which may avoid the use of expensive medical therapy, and the exclusion of ovarian hyperstimulation syndrome (OHSS). These advantages may be offset somewhat by the possible complications of the surgical procedure and its limited duration of ef®cacy, which varies individually. However, in a large number of cases ovulation has been induced for several years. It is interesting to note that ovarian wedge resection, the`predecessor' of LOD, yielded an 88% pregnancy rate, a 78% cumulative live birth rate and a return to a regular menstrual pattern in the majority of the 149 patients followed up for 15±25 years (Lunde et al., 2001) . As LOD is less invasive and causes fewer pelvic adhesions, there is every reason to expect similar or even more impressive results from the technique than present evidence suggests. Those patients who are slim and have high LH concentrations seem to have the most favourable prognosis (Gjonnaess, 1994) .
Ovulation induction with gonadotrophins
WHO Group I
Recent results of treatment with gonadotrophins have not been reported for WHO Group I (hypogonadotrophic-hypogonadism), but two studies report the use of hMG for this group of women covering the period from 1970 to 1989 (Lunenfeld and Eshkol, 1982; Dale et al., 1989) . The two studies included 351 patients who received 958 cycles with a pregnancy rate of 30% per cycle, approximating that observed in women with no infertility problems. A collection of 14 major series published between 1966 (Hamilton-Fairley and Franks, 1990 ) reports cumulative conception rates of 90% for hypogonadotrophic hypogonadic patients after 6 months treatment with hMG. A later series from one centre (Fluker et al., 1994) reported almost identical results. Clearly, pregnancy rates following treatment with hMG in this group of patients surpassed the expected fertility rates in a normal population. For these speci®c cases, a gonadotrophin preparation containing both FSH and LH will yield better results than FSH alone as LH is clearly required to obtain normal circulating estradiol concentrations in gonadotrophin-de®cient women (Schoot et al., 1992) .
WHO Group II
Pregnancy rates in anovulatory women with normal oestrogen concentrations are vastly inferior to those who have no endogenous production of oestrogen due to hypogonadotrophism. The earlier series (Lunenfeld and Eshkol, 1982; Dale et al., 1989) reported pregnancy rates per cycle of just less than 7% for WHO Group II anovulatory patients treated with hMG. A review of 46 studies of WHO Group II patients treated with FSH between 1989 and 1992 (Howles, 1993) reported a pregnancy rate per cycle of 17%, and a further collection of 14 series with hMG reported a cumulative conception rate of 36±63% for this group of patients (Hamilton-Fairley and Franks, 1990) . A clear improvement has been seen over the years, probably in part due to the improvement of monitoring.
The main complications of gonadotrophin therapyÐOHSS and multiple pregnanciesÐare both caused by multiple follicular development. Anovulatory women with PCOS, the vast majority of those comprising WHO Group II, are particularly prone to multiple follicular development when receiving gonadotrophins.
Treatment protocols
Conventional`step-up' treatment with gonadotrophins for women with PCOS who failed to conceive with, or are`resistant' to, clomiphene citrate yields an acceptable cumulative conception rate (Farhi et al., 1993) . However, because of the peculiarly high sensitivity of polycystic ovaries to gonadotrophin stimulation, this form of treatment, employing incremental dose rises of one ampoule (75 IU) every 5±7 days, characteristically induces multiple follicular development, resulting in a high frequency of multiple pregnancies and OHSS (Wang and Gemzell, 1980) . Even in 1990, one review (Hamilton-Fairley and Franks, 1990) reported a mean multiple pregnancy rate of 34% and a severe OHSS rate of 4.6%. In a report from one of our centres, although this protocol produced a cumulative conception rate of 82% after six cycles, it was plagued by an unacceptable rate of multiple pregnancies and OHSS (Homburg et al., 1995) . Supraphysiological doses of FSH (as used in the conventional protocol) provoke an initial development of a large cohort, stimulate additional follicles, and even rescue those follicles destined for atresia (Insler, 1988) . Multiple follicular development is induced by levels of FSH well above the threshold. This statement holds true for gonadotrophin stimulation of the ovaries in all groups of anovulatory patients, and is actually utilized for the induction of superovulation for IVF and embryo transfer. However, for the induction of ovulation in women with PCOS, the problem of achieving the desired monofollicular ovulation is particularly dif®cult and acute due to the extreme sensitivity of the polycystic ovary to gonadotrophic stimulation. The reason for this does not lie in a difference of FSH threshold levels of the polycystic ovaries but is probably due to the fact that they contain twice the number of available FSHsensitive antral follicles in their cohort compared with the normal ovary (van der Meer et al., 1998) . Any dose of FSH overstepping the threshold of the polycystic ovary will, therefore, produce multifollicular development and impending danger of multiple pregnancy and OHSS.
Several investigators have examined the utility of a chronic low-dose regimen of FSH in an attempt to reduce the rate of complications due to multiple follicular development (for a review, see Homburg and Howles, 1999) . The basic thinking behind this regimen is the`threshold theory', which demands the attainment and maintenance of follicular development with exogenous FSH without exceeding the threshold requirement of the ovary (Brown, 1978) . It is a quirk of gynaecological history that the experience of Brown (1978) , who showed that the increase in dose should not exceed around one-third of the preceding dose, went completely unheeded. The principle of the classic chronic low-dose regimen is to employ a low starting dose for 14 days and then use small incremental dose rises (usually 37.5 IU) when necessary, at intervals of not less than 7 days, until follicular development is initiated (Seibel et al., 1984; Polson et al., 1987) . The dose that initiates follicular development is continued until the criteria for giving hCG are attained. The purpose of this form of therapy is to achieve the development of a single dominant follicle rather than the development of many large follicles and so avoid the complications of OHSS and multiple pregnancies.
A comparative prospective study of the conventional regimen with chronic low-dose administration of FSH for anovulation associated with PCOS (Homburg et al., 1995) involved 50 participants. All were treated with FSH, half of them using a conventional stepwise protocol (incremental dose rises of 75 IU every 5±7 days when necessary) and half with a regimen of chronic low dose. Both methods of treatment had an initial dose of 75 IU FSH, but for the low-dose regimen no dose rise was allowed for a minimum of 14 days and, if necessary, increments were of the order of 37.5 IU only for a minimum of 7 days. Compared with the conventional-dose protocol, the chronic lowdose regimen yielded slightly improved pregnancy rates (40 versus 24%) while completely avoiding OHSS and multiple pregnancies, which were prevalent (11% OHSS and 33% multiple pregnancies) with conventional therapy. Uniovulation was induced in 74% versus 27% of cycles and the total number of follicles >16 mm and estradiol concentrations were half those observed on conventional therapy. A large French multicentre study (Hedon et al., 1998) with an identical objective and protocol design compared conventional and chronic low-dose regimens in 103 anovulatory WHO Group II women. The comparison of low with conventional dose revealed pregnancy rates of 33.3 versus 20%, and with a multiple (twins) pregnancy rate of 14 and 22%, respectively. The total number of follicles >10 mm and estradiol concentrations on the day of hCG in the low-dose group were half those seen on conventional therapy. Additionally, the low-dose regimen tended to produce a higher rate of mono-or bifollicular development in this study.
A compilation of reported results from the literature, using a chronic low-dose protocol identical to that described above, is presented in Table I . The prominent features include a remarkably consistent rate of uniovulatory cycles of around 70% in each series. The pregnancy rate of 40% of the patients and 20% per cycle are acceptable judging from past experiences with conventional therapy and taking into account that many of the patients comprising these series received only one cycle of therapy. However, the justi®cation for the adoption of the chronic low-dose protocol may be seen in the extraordinarily low prevalence of OHSS and a multiple pregnancy rate of 5.7%, twins in all cases except two. It should be remembered that these encouraging results were obtained in a large number of women with clomiphene-resistant PCOSÐa particularly troublesome group to treat with gonadotrophin therapy.
The majority of patients on a low-dose protocol develop a single large follicle meeting hCG administration criteria within 14±16 days without any change in the initial dose for 14 days (Serono International, 1995; White et al., 1996) . In the relatively unusual case (often in very obese women) where a treatment cycle is abandoned after 28±35 days due to lack of response, a larger starting dose may, of course, be employed in a further attempt. The strict adherence to a 14-day starting period using a persistent dose has taxed the patience of several practitioners using the lowdose regimen, and some have reduced this to 7 days A possible criticism of the chronic low-dose step-up regimen is that, unlike the events of the normal ovulatory cycle in which decreasing FSH concentrations are seen throughout the follicular phase, FSH levels may be elevated during the late follicular phase (Dale et al., 1993) . This could induce multi-rather than monofollicular ovulation. In order to mimic more closely the events of the normal ovulatory cycle, Fauser's group use a stepdown dose regimen with a starting dose of 150 IU and decrease the dose by 0.5 ampoules when a follicle of 10 mm ensues and by the same amount every 3 days if follicular growth continues van Dessel et al., 1995) . A comparison of this regimen with the classic step-up regimen (van Santbrink and Fauser, 1997) demonstrated a monofollicular growth rate of 88% of cycles in the step-down regimen compared with 56% with the step-up protocol. In the step-down group, the median duration of treatment was signi®cantly reduced by half to 9 days, and a mean of six ampoules less were needed than when using the classic step-up dose regimen. Yet another variation on the theme is the sequential step-up and step-down regimen (Hugues et al., 1996) in which the FSH threshold dose is reduced by half when the leading follicle reaches a diameter of 14 mm. When compared with a step-up protocol (increments of 37.5 IU every 6 days) a signi®cantly smaller number of intermediate size follicles was produced and mid-luteal phase estradiol concentrations were also signi®cantly lower (350 T 77 and 657 T 104 pg/ml respectively).
Gonadotrophin preparations used in low-dose protocols
The various gonadotrophin preparations now available commercially have prompted the question of which would prove most effective for use in a chronic low-dose regimen. A comparative, randomized study of low-dose human menopausal gonadotrophins (hMG, 75 IU FSH + 75 IU LH) versus`puri®ed' urinary hFSH (u-hFSH) was performed in 30 women with PCOS over 75 cycles (Sagle et al., 1991) . In this study, there were no differences in ovulation and pregnancy rates or the number of monovulatory cycles induced by the two preparations. The authors suggested that the success of treatment depends on the low dose of hormone used rather than the presence or absence of LH in the preparation. Two large, randomized, multicentre studies have compared puri®ed u-hFSH with recombinant-hFSH using the classic low-dose protocol in women with WHO Group II anovulatory infertility. The ®rst study (Serono International, 1995) did not demonstrate signi®cant differences in safety or ef®cacy. The second study (Coelingh-Bennink et al., 1998), while demonstrating an apparent higher in-vivo potency of r-hFSH, did not demonstrate any differences in ovulation or pregnancy rates. Finally, a study from Spain (Balasch et al., 1998) compared r-hFSH with a highly puri®ed urinary preparation of FSH. These authors concluded that r-hFSH has a higher in-vivo biopotency than highly puri®ed u-hFSH as judged by follicular development, hormonal levels and amount of FSH required. No conclusions regarding clinical pregnancies could be drawn due to the small sample size. Patient compliance ultimately in¯uences overall results, and although the chronic low-dose protocol is often more prolonged than the conventional protocol, this inconvenience may be eased by self-administration of gonadotrophins and by making use of the more potent r-hFSH. It is our practice to examine the initial ovarian response after 7 full days only and thereafter according to response so that the number of clinic visits may be kept to a minimum.
While the results of the classic low-dose regimen are satisfyingÐparticularly in terms of the almost complete elimination of the incidence of OHSSÐthere is clearly still room for improvement. The multiple pregnancy rate may be reduced still further by a strict adherence to the criteria for giving hCG. If hCG is withheld in the presence of three or more follicles >15 mm, the multiple pregnancy rate may be reduced to a minimum. The Serono series (Ares-Serono, 1995) clearly demonstrated the signi®cant trend and correlation between the number of large follicles produced and the incidence of multiple pregnancies (Table II) . It should be pointed out that the individually adjusted treatment scheme, which allows for an increase or decrease in the gonadotrophin dose according to the patient's response, is capable of reducing the multifollicular development by providing enough gonadotrophins for a certain number of follicles but insuf®cient for supporting and/or saving all initially mobilized follicles from atresia. This is useful in decreasing the rate of multiple pregnancies and the incidence of OHSS (Lunenfeld, 1963; Insler et al., 1970) .
For women with PCOS, treatment with a chronic low-dose regimen of gonadotrophins has almost completely eliminated the very troublesome complication of OHSS. In addition, it has reduced the multiple pregnancy rate to a reasonable minimum while maintaining an acceptable pregnancy rate.
Ovulation induction with pulsatile GnRH
For patients who have anovulation due to hypogonadotrophic hypogonadism but have an intact pituitary gland, then treatment with pulsatile GnRH is tailor-made. Administered through an infusion pump, either subcutaneously in a dose of 15±20 mg per bolus or intravenously, 5±10 mg per bolus, one pulse every 60±90 min, this treatment is safe, simple and effective and has many advantages over gonadotrophin therapyÐespecially for patients with idiopathic hypogonadotrophic hypogonadism and weight loss-related amenorrhoea (Homburg et al., 1989) . The GnRH pulses stimulate an endogenous,`physiological' release of FSH and as a consequence, subsequent events closely simulate those of a normal ovulatory cycle. Following ovulation, the pump may either be continued throughout the luteal phase or discontinued and luteal phase support given.
Compared with gonadotrophin treatment, pulsatile GnRH therapy needs little or no monitoring and yields a much higher rate of monofollicular ovulation. Hence, multiple pregnancy rates are very low and severe OHSS essentially does not occur. Cumulative pregnancy rates of 80±93% after six cycles have been achieved (Homburg et al., 1989; Braat et al., 1991) with a multiple pregnancy rate of 4±5% and miscarriage rates similar to those in the healthy population. Treatment with pulsatile GnRH has been tried in women with PCOS, but with much less success (Homburg et al., 1989; Filicori et al., 1991) and has largely been abandoned for this indication. Side effects with the GnRH pump are minimal and are mostly concerned with local irritation at the site of the needle or thrombophlebitis following intravenous administration.
Pulsatile GnRH therapy is little used because patient acceptance has been low; many patients were put off by the idea of continuing their daily routine accompanied by a mini-pump and a needle inserted either subcutaneously or intravenously.
GnRH agonists in ovulation induction
The useful properties of the GnRH agonists and antagonists basically concern their ability to suppress FSHÐand, more importantly, LH concentrationsÐbefore and during ovarian stimulation. The place of GnRH agonist co-treatment in IVF is routine and not really disputed. It confers the advantages of eliminating, almost completely, the annoying occurrence of premature luteinization. In addition, some investigators have reported more pregnancies, possibly better quality oocytes and fewer miscarriages. Their possible application during ovulation induction should therefore be particularly relevant in the presence of the chronic, tonic, high serum concentrations of LH observed in a high proportion of women with PCOS. In theory, their prudent use should avoid premature luteinization, relatively low pregnancy rates and the high miscarriage rates witnessed in this group of patients (Homburg, 1996) . In a large study , 239 women with PCOS received hMG with or without GnRH agonist for ovulation induction or superovulation for IVF/ embryo transfer. Of pregnancies achieved with GnRH agonist, 17.6% miscarried compared with 39% of those achieved with gonadotrophins alone. Cumulative live birth rates after four cycles for GnRH agonist were 64% compared with 26% for gonadotrophins only.
For ovulation induction in PCOS, our experience and that of others has shown an increased pregnancy rate and lower miscarriage rate in women receiving combination treatment of agonist and gonadotrophins when tonic LH concentrations are high. However, the agonist has not become standard treatment. There are several reasons for this apparent anachronism. When GnRH agonist is added to conventional or low-dose gonadotrophin therapy, treatment becomes more cumbersome, longer, requires more gonadotrophins to achieve ovulation, and has a greater prevalence of multiple follicle development and consequently more OHSS and multiple pregnancies. It is for these reasons that this combination therapy should be con®ned to women with high serum concentrations of LH who have repeated premature luteinization, who stubbornly do not conceive on gonadotrophin therapy alone, or who have conceived and had early miscarriages on more than one occasion.
As to the question of whether GnRH agonists can help to reduce the problem of OHSS and multiple pregnancies in PCOS ovulation induction, the answer is categorically no. If anything, combining GnRH agonist with gonadotrophin stimulation will exacerbate the problem of multiple follicular development and therefore increase rates of cycle cancellation, OHSS and multiple pregnancy (Homburg et al., 1990; Van der Meer, et al., 1996) . This may be due to several factors: loss of the endogenous feedback mechanism when using GnRH agonist, reduction of intra-follicular androgen levels following pituitary down-regulation and consequently postponed atresia and, most probably, greater stimulation of follicles by the larger amounts of gonadotrophins needed when using GnRH agonist. Regardless of the reasons, GnRH agonist is not the solution to the problem of multiple follicular development.
As mentioned above, the two main complications of ovulation induction for PCOS are multifollicular development and the possible deleterious effects of high LH levels, low conception rates and high miscarriage rates. Reason would have it that a combination of chronic low-dose FSH stimulation with GnRH agonist therapy would yield the best results. Others (Scheele et al., 1993) studied women with PCOS undergoing ovulation induction with chronic low-dose FSH therapy, one group with and one without adjuvant GnRH agonist therapy. Monofollicular ovulation was achieved in just 14% of the agonist cycles compared with 44% of those treated with low-dose FSH alone. Not only did GnRH agonist not abolish the inter-and intra-individual variability of the FSH dose required to induce ongoing follicular growth, but it also seemed to induce an even further increase in the sensitivity of the PCO follicles to gonadotrophin stimulation once the threshold FSH dose had been reached.
Possible contribution of GnRH antagonists
As yet, there have been no serious speci®c clinical trials of the incorporation of GnRH antagonists into ovulation induction protocols for PCOS. As for some optimistic speculation, the antagonists have some advantages over the agonists and these may well be utilized in the treatment of anovulatory PCOS. First, antagonists act by the mechanism of competitive binding and this allows a modulation of the degree of hormonal suppression by adjustment of the dose. Further, antagonists suppress gonadotrophin release within a few hours, have no¯are-up effect, and gonadal function resumes without a lag effect following their discontinuation. If these advantages are applied to an ovulation induction protocol for PCOS, it can be visualized that when used in combination with low-dose FSH administration the antagonist be given in a single or repeated doses when a leading follicle of 13±14 mm is produced. This would in theory prevent premature luteinization, protect the oocyte from deleterious effects of high LH concentrations, and still allow the follicle to grow unhindered to ovulatory size. Compared with agonist-treated cycles this would confer the (again) theoretical advantages of a much shorter cycle of treatment, promise more conceptions and fewer miscarriages, reduce the amount of gonadotrophin required and increase the incidence of monofollicular ovulation with a consequent reduction in the prevalence of OHSS and multiple pregnancies. It remains to be seen if these ambitious goals are achievable.
Ovarian hyperstimulation syndrome (OHSS)
Ovarian hyperstimulation, the most serious complication of medical induction of ovulation, is a potentially life-threatening, iatrogenic disorder. The syndrome occurs when treatment with ovulation-inducing drugs results in the development and growth of multiple follicles which, when luteinized, produce excessive quantities of peptides regulating the growth and permeability of blood vessels (Insler and Lunenfeld, 1997) . The ®nal effect of this sequence of events may be a massive¯uid shift and recompartmentalization resulting in hypovolaemia on the one hand and in oedema, ascites, hydrothorax or hydropericardium on the other hand. This, in consequence, may lead to impaired function of the heart, kidneys and liver as well as to thromboembolic phenomena, one of the life-threatening complications of OHSS. The incidence of moderate and severe hyperstimulation compiled from more than 11 300 ovulation induction cycles reported in the literature varied from 3.1 to 6% and from 0.25 to 1.8% respectively . Later, others (Grudzinskas and Egbase, 1998) still maintained that clinically relevant ovarian hyperstimulation occurs in up to 10% of cycles and in 0.5±2.0% of cycles may become a life-threatening complication. OHSS was also found to be associated with a higher pregnancy rate, indicating that to cause mild OHSS might be bene®cial for increasing the pregnancy rate (Tulandi et al., 1984) .
It must, however, be noted that arti®cially enhanced follicular development has its dark sides above and beyond the possibility of clinical hyperstimulation. It was shown in different species, including humans, that oocytes from stimulated ovaries have a reduced potential to implant (Wetzels et al., 1998; Kikuchi et al., 1999; Olson and Seidel, 2000) . Others noted that in women with severe ovarian hyperstimulation the abortion rate was signi®-cantly increased (Raziel et al., 2002) , while it was also observed that the incidence of apoptotic cumulus granulosa cells was much higher in stimulated as compared with natural cycles (Kaneko et al., 2000) .
It would be far beyond the scope of this review to dwell on the pathophysiological mechanisms leading to the development of OHSS, to describe in detail classi®cation of symptoms and signs of the syndrome, or to discuss available treatment schemes. However, OHSS is certainly part and parcel of ovulation induction and any comment on this topic must also take a stand with regard to the inherent risk/bene®t problem.
It must be realized and accepted that OHSS is a disorder which, at present, cannot be entirely avoided. It is certainly true that correct classi®cation of OHSS when it appears and promptÐ and when necessaryÐaggressive therapy can dramatically improve the outcome of the disease. On the other hand, attempts to prevent the appearance of ovarian hyperstimulation have been less successful. Several preventive measures have been proposed:
1.`Coasting' (Sher et al., 1993; Waldenstrom et al., 1999) . 2. Follicular reduction (Balaisch et al., 1988; De Geyter et al., 1996; Egbase et al., 1997 Egbase et al., , 1999 .
3. Postponing embryo transfer and replacing frozen embryos in subsequent non-stimulated cycles (Awonuga et al., 1996; Queenan et al., 1997) .
4. Flanking the ovulatory dose of hCG with administration of human albumin (Asch et al., 1993; Shoham et al., 1994) .
5. Replacing the ovulatory dose of hCG with GnRH analogue (Gonen et al., 1990; Emperaire and Ruf®e, 1991; Itskovitz et al., 1991) .
6. Replacing the ovulatory dose of hCG with recombinant LH (The European Recombinant LH Study Group, 2001) .
Although each of these methods had a measure of success, none has been able to completely prevent the appearance of severe ovarian hyperstimulation or to ensure genuine attenuation of its course.
In practice there are only two methods that are really ef®cient in preventing OHSS: (i) using very gentle ovarian stimulation protocols; or (ii) withholding the administration of hCG and abandoning the treatment cycle. It is clear that the milder the ovarian stimulation, the less the number of follicles that will develop and threaten the appearance of hyperstimulation. However, the less the number of follicles mobilized and sustained, the less oocytes will be harvested in IVF and the lower will be the chance for a pregnancy.
Withholding the ovulatory dose of hCG is obviously not an easy decision considering the ®nancial and psychological price of discarding many days of preparations and treatment. Moreover, women prone to OHSS may develop the syndrome in several consecutive cycles despite all precautions.
Gentle stimulation and cycle cancellation when appearance of OHSS is suspected, ®t the aims of treatment of anovulation, i.e. stimulating mono-ovulation and obtaining a singleton pregnancy. This principle is, however, less suitable to the basic philosophy of fertility enhancement, i.e. induction of multiple ovulation in ovulatory women with spontaneous menstrual cycles. Indeed, this attitude does not exactly conform to the therapy using COH and IUI, and has not been genuinely accepted by many IVF clinics. The main argument used by proponents of IVF as a fertility panaceum is its ef®ciency and success rate. However, it is almost impossible to compare the cost of an additional IVF or COH + IUI treatment required because the previous cycle was cancelled in order to avoid OHSS with the price tag of hospital treatment of severe hyperstimulation or the charges for a triplet delivery or the ®nancial social and psychological burden of raising a child handicapped by premature birth. Large epidemiological and social studies of the results of infertility treatments and all their implications are glaringly needed.
After the tremendous success of modern reproductive technologies, the time has come to reassess some of our approaches to treatment of infertility. We now have all the drugs and methods to offer ef®cient treatment to the vast majority of childless couples. It is our duty to use these means with more restraint and to estimate the results achieved not only through the magnifying glass of implantation indices, pregnancy rates and deliveries per embryo transfer but also to judge our success or failure from a wider angle of the value of medical services we provide to the population we serve.
The changing scope of ovulation induction
Ovulation induction by application of human gonadotrophins was primarily designed as substitution therapy for women with hypogonadotrophic hypogonadism.
Both types of substitution therapy, either supplying the lacking GnRH by pulsatile administration of a synthetic preparation or directly stimulating the ovaries by gonadotrophin extracts, enabled the achievement of pregnancy in 70±80% of women with hypogonadotrophic amenorrhoea after four cycles of therapy Tadokoro et al., 1997) . However, the group of women suffering from this condition is very small. The majority of patients who seek medical help because of infertility due to anovulation do not show real lack of gonadotrophin secretion and only a few of them have amenorrhoea. In these women the main problem is some disturbance of feedback mechanism, i.e. improper signals between the ovary, the pituitary gland and the hypothalamus, regardless of the precise nature and localization of the disorder. The majority of this group present with oligomenorrhoea, and many have signs or symptoms of PCOS. The raison d'e Ãtre of therapy in this group is to stimulate ovarian function in a manner as close to the natural pattern as possible in order to achieve a singleton pregnancy.
According to these principles, during the next two decades (1965±1985) infertile anovulatory women, except for those with hyperprolactinaemia, were classi®ed into two main groups:
d Group I: women with primary or secondary amenorrhoea, low levels of gonadotrophins and negligible endogenous oestrogen activity. d Group II: patients with anovulation associated with a variety of menstrual disorders who exhibit distinct endogenous estrogen activity and gonadotrophin levels within the normal range.
Group I received substitution therapy using either pulsatile GnRH or human gonadotrophin preparations, while Group II was initially treated with clomiphene and offered gonadotrophin therapy if this treatment failed to result in pregnancy.
It is true that for many years some fertility clinics have also attempted ovulation induction in apparently ovulatory women with regular menses, mainly in couples with unexplained infertility, in order`to improve ovulation', but this was done rather surreptitiously because to stimulate the ovaries in women who apparently ovulated spontaneously was considered by manỳ contradictio in adiecto'.
IVF, which was initially considered to be a speci®c therapy for severe mechanical infertility, very soon began to be applied also for treatment of patients with a moderate male factor and couples with unexplained infertility. Since COH was almost from the beginning the basic tenet of IVF, it seemed logical to apply this principle to treatment of couples with unexplained infertility without the inconvenience, complexity and cost of IVF (Berenstein et al., 1980; Nulsen, 1993; Mascarenhas et al., 1994; Hughes et al., 2000) .
Unexplained infertility' is a fastidious misnomer designed to cover up the ineptitude of medicine rather than to signify a distinct medical entity. An endless battery of tests was proposed for diagnosing unexplained infertility, some requiring anaesthesia or surgical intervention, others time-consuming or expensive but none was able to provide unequivocal diagnosis. A compact diagnostic package accepted by the majority of fertility centres was never achieved. Hence, the incidence of unexplained infertility varies from 1.4 to 50% in different series (Bettendorf, 1986; Insler and Lunenfeld, 1995; Templeton, 1995; Redmond and Harrison, 2000) .
Our group proposed to use the term`multifactorial subfertility' in order to cover a large assembly of couples with transient anovulation, mild or moderate oligoasthenoteratospermia (OAT), cervical factor, possible mild endometriosis and unexplained infertility in whom the only ®xed feature has been their inability to attain pregnancy after practising unprotected intercourse during 2 years or more, but in whom no de®nite signs of mechanical, hormonal or severe male infertility were found (Insler and Lunenfeld, 1995, 1997) . Since in this group transient disturbances of both ovulation and sperm quality are quite frequent, it was proposed that therapy should consist of COH combined with IUI using the husband's sperm improved by washing, by swim-up through culture media or by passing through a Percoll column. Indeed, the addition of IUI to COH by clomiphene or gonadotrophins was shown to be signi®cantly more effective than COH alone (Arcaini et al., 1996; Hughes, 1997; Zeyneloglu et al., 1998) . Several authors found the combined COH + IUI treatment to be very effective in unexplained and mild male infertility (Aboulghar et al., 1993; Zayed et al., 1997; van Voorhis et al., 2001) . One report (Tadokoro et al., 1997) provided additional support for the effectiveness of combining IUI with ovulation induction in the unexplained infertility group. These authors attempted to induce ovulation and conception with human gonadotrophins (without IUI) in women with either hypogonadotrophic or eugonadotrophic hypogonadism (n = 91), with PCOS (n = 148) or unexplained infertility (n = 117). The cumulative pregnancy rates after four cycles were 74, 70 and 38% in the three groups respectively. Their conclusion sounded as if it were written especially for this review:`...correction of unexplained infertility may involve more than simple correction of a possible subtle ovulatory defect'.
Thus, at present, three different types of ovarian stimulation are employed:
1. Substitution therapy: offered to women with amenorrhoea due to relative gonadotrophin de®ciency.
2. Regulation therapy: applied in patients exhibiting oligo-or persistent anovulation.
3. COH: together with IUI, this is used in couples with multifactorial subfertility', i.e. mild endometriosis, transient anovulation, mild OAT, cervical mucus inadequacy or hostility, unilateral tubal occlusion or, quite frequently, a combination of more than one of the above-mentioned disturbances.
Women suitable for substitution therapy usually respond very well to this treatment and have a 70±80% rate of conception after four cycles Tadokoro et al., 1997) . IUI may be applied when mild male factor is present and ICSI is reserved only for cases with severe OAT or azoospermia. Unfortunately this group, though ideal for gonadotrophin therapy, is rather small and most fertility clinics do not see more than two or three new patients of this type per year.
Regulation therapy is reserved for patients with oligo-or persistent anovulation. The majority of these women have polycystic ovaries, in some of them accompanied also by clinical symptoms or hormonal ®ndings of PCOS. The experience with clomiphene citrate, and gonadotrophins following clomiphene failure, has certainly been satisfying in this group of patients. At this point in time, there are insuf®cient data available to establish which patients have also a fair chance to ovulate when treated with metformin alone and who would bene®t more from therapy combining metformin with clomiphene or gonadotrophins (Anderson et al., 1998; Imani et al., 2000; Ng et al., 2001; Nestler et al., 2002; Yarali et al., 2002) .
The medical, social and psychological pro®le of patients with PCOS who should be offered ovarian drilling as a ®rst-line therapy of their infertility has yet to be determined. A clear protocol stating whether ovarian electrocautery should precede ovulation induction therapy (Colacurci et al., 1997) or how many unsuccessful clomiphene or gonadotrophin cycles should be given before ovarian drilling is recommended is also still missing. At which point of the whole therapeutic sequence should IVF be offered and whether women with PCOS are better or worse candidates for IVF than patients with normal ovaries remains a matter of debate (Aboulgar et al., 1997; Beckers et al., 1999; Engman et al., 1999) .
There is no doubt that couples with multifactorial subfertility (see above) represent the most numerous group of patients in many fertility centres. It is our belief that these couples should be treated with COH combined with IUI for a number of trials (three to six clomiphene treatments and four gonadotrophin cycles) before IVF is considered.
Concluding remarks
The rising numbers and improving results of IVF programmes has brought about the debate of whether today IVF should be offered as ®rst-line therapy to all infertile couples, regardless of type of infertility. One group (Gleicher and Karande, 2001) had suf®cient courage to propose this in public; many colleagues agree with this proposition in private, and some already practice it in their clinics.
The present authors consider that it would probably be carelessÐand certainly immatureÐto implement this therapeutic design at present. They believe that IVF (with or without ICSI) should be offered as primary treatment to infertile patients with distinct mechanical infertility, severe male infertility as well as to those requiring oocyte donation or surrogate mother arrangements. However, at this stage, women with hypogonadotrophic hypogonadism or with polycystic ovaries should be offered classical ovulation induction, while couples with unexplained infertility (better labelled as`multifactorial subfertility') should still be exposed to COH by clomiphene or gonadotrophins together with IUI, and transferred to IVF programmes only after this therapy has failed to produce pregnancy. This suggestion is based on the following considerations:
1. The ef®ciency of IVF is still limited. In Europe in 1998 and in the United States in 1999, the overall pregnancy rates per retrieval were 23.2 and 35% respectively (CDC-Reproductive Health, 1999; Nygren and Andersen, 2001) . It should also be noted that both in the US and in Europe, not all functioning IVF clinics report their results to the central registries.
2. Oocyte retrieval in IVF represents a surgical intervention and requires general anaesthesia in the majority of cases. COH and IUI are unequivocally less complicated and safer compared with IVF. Moreover, a degree of suspicion has been raised as to the outcome of pregnancies and possible untoward in¯uence on infants born after IVF with and without ICSI (Bonduelle et al., 2002; Hansen et al., 2002; Schieve et al., 2002; Stromberg et al., 2002) . These ®ndings must create some concern, though it should be pointed out that no studies of such magnitude have been performed on children resulting from COH + IUI.
3. Compared to IVF, COH + IUI is less ef®cient on a per cycle basis, but is nevertheless capable of producing a pregnancy within a reasonable time. One group (Khalil et al., 2001 ) reported a clinical pregnancy rate of 11.9% per cycle and a birth rate of 27.2% after a mean of 2.8 cycles in 893 couples treated by COH + IUI. Others (Van Voorhis et al., 2001 ) summarized their experience with 3479 IUI cycles in 1039 infertile couples. The conclusion stemming from these studies is that, in the group of unexplained infertility (or better`multifactorial subfertility') with a female partner aged less than 40 years and a male partner having more than 10Q10 6 total motile sperm in the ejaculate, COH + IUI is a logical and ef®cient ®rst-line therapy.
4. COH coupled with IUI is much more cost-effective than IVF. Several publications dealing with the economics of infertility treatment showed that a pregnancy or a live birth achieved by IVF was between 2.4 and 3.7 times more expensive than that obtained by COH + IUI (Zayed et al., 1997; Guzick et al., 1998; Goverde et al., 2000; Philips et al., 2000) .
It is clear that in the presence of potent treatment modalities, and in keeping with the needs and habits of a society of achievement constantly reshaped by mass media, the treatment of infertility must be well-planned, ef®cient and provide results within a reasonable time.
Since the age of the female partner is the most important single factor deciding the outcome of all types of fertility therapy (excluding oocyte donation) (Templeton, 1998) , it is clear that in women aged over 35 years the diagnostic and therapeutic sequences must be more concise, less time-consuming and may be more aggressive than in younger patients. In all couples, however, a balance between success rates and the risk, cost and patients' effort must be fervently safeguarded.
